GC012F CAR-T Cell Injection

DRUG3 trials

Sponsors

Daishi Tian, Institute of Hematology & Blood Diseases Hospital, China, Huashan Hospital

Conditions

Multiple SclerosisRheumatoid Arthritis

Early Phase 1

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

RecruitingNCT07303790

Daishi TianMultiple Sclerosis

Start: 2026-03-09End: 2028-12-10Target: 9Updated: 2026-05-22

An Open-label Study of GC012F in Rheumatoid Arthritis.

WithdrawnNCT07315503

Institute of Hematology & Blood Diseases Hospital, ChinaRheumatoid Arthritis

Start: 2027-12-01End: 2041-01-15Updated: 2026-06-10

This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

WithdrawnNCT07364487

Huashan HospitalMultiple Sclerosis

Start: 2026-01-26End: 2026-03-25Updated: 2026-03-30